−515KRW
−21.95 BKRW
12.70 BKRW
44.59 M
About KANGSTEM BIOTECH
Sector
Industry
CEO
Jong-Cheon Na
Website
Headquarters
Seoul
Employees (FY)
113
Founded
2010
ISIN
KR7217730001
FIGI
BBG00BDZ1NT0
KANGSTEM BIOTECH Co., Ltd. engages in the manufacture, development, and sale of stem cell therapy products. Its services include next generation and gene-loaded stem cell. The company was founded by Kyung-Sun Kang on October 29, 2010 and is headquartered in Seoul, South Korea.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 217730 is 2650 KRW — it has increased by 14.72% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on KRX exchange KANGSTEM BIOTECH stocks are traded under the ticker 217730.
217730 stock is 15.80% volatile and has beta coefficient of 1.40. Check out the list of the most volatile stocks — is KANGSTEM BIOTECH there?
Yes, you can track KANGSTEM BIOTECH financials in yearly and quarterly reports right on TradingView.
217730 stock has risen by 8.61% compared to the previous week, the month change is a 38.02% rise, over the last year KANGSTEM BIOTECH has showed a 3.76% decrease.
217730 net income for the last quarter is −4.99 B KRW, while the quarter before that showed −5.51 B KRW of net income which accounts for 9.53% change. Track more KANGSTEM BIOTECH financial stats to get the full picture.
Today KANGSTEM BIOTECH has the market capitalization of 129.22 B, it has decreased by 13.01% over the last week.
No, 217730 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 217730 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade KANGSTEM BIOTECH stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 113.00 employees. See our rating of the largest employees — is KANGSTEM BIOTECH on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So KANGSTEM BIOTECH technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating KANGSTEM BIOTECH stock shows the buy signal. See more of KANGSTEM BIOTECH technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. KANGSTEM BIOTECH EBITDA is −18.52 B KRW, and current EBITDA margin is −152.63%. See more stats in KANGSTEM BIOTECH financial statements.